OR WAIT null SECS
© 2023 MJH Life Sciences and Pharmaceutical Executive. All rights reserved.
© 2023 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
Pharm Exec’s 19th annual report on the trends of the day in drug development examines the surging investment in new treatments and advances for so-called “first-world” conditions.
How pharma companies can reduce the risk of failure with AI-based innovations.
A look at the performance of the top 15 companies across seven business-key metrics, including the latest standouts in market capitalization and creating shareholder value.
Check out the latest issue of Pharmaceutical Executive!
December 08, 2023
FDA approval of bluebird bio’s Lyfgenia and Vertex Pharmaceuticals' and CRISPR Therapeutics’ Casgevy marks significant milestone in the treatment of sickle cell disease.
Farbman discusses the struggles that pharma companies are facing when trying to raise funds and how this is impacting IPOs.
Pharma companies must embrace the future to advance commercialization.
PREPVACC study expected to stop further HIV vaccination attempts after previously enrolling 1,500 participants in East and Southern Africa.
Camille Lee explains the ins and outs of the patient support system for psoriasis medication.
December 07, 2023
Arthritis, asthma, cancer, cardiovascular diseases, chronic kidney disease, COPD, depression, and diabetes reach the highest recorded levels since the America’s Health Rankings Annual Report began tracking them in 1990.
Migraine with comorbid obesity have been found to cause high levels of disability and are both more common in female patients.
Trial of Keytruda (pembrolizumab) plus chemotherapy and maintenance Lynparza (olaparib; AstraZeneca, MSD) for the treatment of metastatic squamous non-small cell lung cancer stopped after data did not show a survival benefit.
December 06, 2023
UCB executive speaks on recent FDA approval of Bimzelx.
Experts from Hootsuite noted that the primary social media ROI concern for healthcare companies is the time and money it takes to maintain a multi-platform presence.